Method to treat HPV Infection and Prevent Cancer with COX-2 Inhibitors
- *Abstract
-
Drs. Andrew Dannenberg and Kotha Subbaramaiah of the Weill Cornell Medical College are world thought leaders in the use of COX-2 inhibitors to treat and prevent cancer.
Infections with certain human papillomavirus types (HPVs) constitute the major risk factor for the development of cervical cancer and some forms of penile cancer. Multiple cellular regulatory pathways are subverted as a direct consequence of an infection with a high-risk HPV. For instance, the HPV E6 and E7 oncoproteins form complexes with and functionally inactivate the p53 and the retinoblastoma tumor suppressors, respectively.
The Cornell investigators have demonstrated in vitro that COX-2 inhibitors and certain other compounds (such as PPAR-gamma ligands) can stop oncogenic signalling caused by these viruses.
Cornell has an issued US patent on the use of COX-2 inhibitors to treat and prevent HPV-caused cancers; the applications in Europe and Canada retain claims to other types of compounds as well.
- *Licensing
- BrianJ. Kellybjk44@cornell.edu212-746-6186
- 其他
-
- (2004) Golijanin D, et al. Cyclooxygenase-2 and microsomal prostaglandin E synthase-1 are overexpressed in squamous cell carcinoma of the penis. Clin Cancer Res.10(3):1024-31.
- (2005) Wu R, et al. Epidermal growth factor-induced cyclooxygenase-2 expression is mediated through phosphatidylinositol-3 kinase, not mitogen-activated protein/extracellular signal-regulated kinase kinase, in recurrent respiratory papillomas. Clin Cancer Res. 11(17):6155-61.
- (2007) Subbaramaiah K, Dannenberg AJ. Cyclooxygenase-2 transcription is regulated by human papillomavirus 16 E6 and E7 oncoproteins: evidence of a corepressor/coactivator exchange. Cancer Res.67(8):3976-85.
- 国家/地区
- 美国
